News Archive

The University of Maryland Institute for Bioscience and Biotechnology Research (IBBR) invites you to participate in the 5th Biennial NMR Day symposium on Friday, May 17, 2013, at our facility in Rockville, Maryland.

IBBR (formerly CARB) hosts a biennial meeting, designed to promote discussion and collaboration among scientists active in the application of biomolecular NMR to modern problems in structural biology and biotechnology. The symposium speakers are internationally recognized in the application of NMR to biological systems

Emergent BioSolutions Inc. (NYSE:EBS) announced its participation in the Defence against Terrorism Programme of Work (DAT POW) workshop conducted by the North Atlantic Treaty Organization (NATO) Emerging Security Challenges Division at the Counter Terror Expo in London. An initial session of the workshop was focused on the future capabilities and protection of the Special Operations Forces (SOF) community on areas such as Improvised Explosive Devices (IEDs), Intelligence, Surveillance, Reconnaissance (ISR), Biometrics and Forensics, Information Sharing Systems, Tactical Computer, Communications, Command and Control (C4), and Force Protection.

“Emergent strongly supports NATO’s initiatives to educate on protecting those who protect the population,” said Allen Shofe, Executive Vice President of Corporate Affairs, Emergent BioSolutions. “NATO DAT POW workshops are highly relevant and informative as they cover various activities undertaken and coordinated by NATO countries.”

TOPIC: 

Leveraging USDA-ARS Partnerships and Capabilities to Help Your Business

PRESENTERS:  

Robert Griesbach, Ph.D.
Deputy Assistant Administrator Office of Technology  

James Poulos, III
Technology Transfer Coordinator  

Cathy Cohn
Technology Transfer Liaison      

Abstract:  

Agricultural Research Services (ARS) is the research arm of the Department of Agriculture that develops and transfers solutions to agricultural problems affecting Americans every day, from field to table.  To accelerate the development of new products and help move technologies into the marketplace, ARS often partners with companies and research institutions early on in the research process.  Working collaboratively alongside ARS, partners are able access and implement ARS technologies, resources and expertise to further develop specific products and create new ones.  ARS conducts research in 800 projects at 90 locations including six pilot plants and six human nutrition centers.  With a long standing commitment to technology transfer, ARS works closely with the private sector to ensure research outcomes are adopted.  Please join us to learn about the wide range of expertise and capabilities from ARS that can be used to grow your business  

The National Capitol Area Local Chapter of SoPE in concert with JHU Carey Business School, MedChi, Zanvyl Krieger School of Arts and Sciences Center for Biotechnology Education, Montgomery County Medical Society, and the Medical Society of Northern Virginia presents:

“Working with Industry in the Life Sciences – What does it Really Take?”

Tuesday, May 14th, 2013–6:00PM to 8:00PM

Johns Hopkins University, Montgomery County Campus, Building III – 9605 Medical Center Drive, Room 121

Johns Hopkins says it is working on its largest-ever fundraising campaign, which aims to raise $4.5 billion by the end of 2017.

The university and health system announced the effort Saturday. The idea is to create as many as 300 endowed professorships and generate nearly $700 million for undergraduate financial aid and graduate student fellowships.

The Ernst & Young Entrepreneur Of The Year 2013 finalists have a lot to celebrate. They’ve built their dream companies. Expanded. Innovated. And now Ernst & Young is recognizing them for their achievements. Help us congratulate these outstanding entrepreneurs. Join us at this years event and see who will take home top honors.

Somewhere between venture funding and bank loans is a kind of investment that seems to fly under the radar, but apparently over the last several years has become increasingly popular for biotech companies beyond the startup stage looking for growth capital.

Royalty financing is the vehicle that Capital Royalty L.P. will use to invest its new $805 million fund in healthcare products and technologies. But (sorry startups), it’s not looking for early-stage companies. Capital Royalty says it invests in companies with FDA-approved healthcare products that are generating revenue. These are companies looking to make acquisitions, expand into new markets or develop new products with investments of $20 million to $200 million.

Late last week, leaders from across the global vaccine industry gathered at the 6th Annual Vaccine Industry Excellence (ViE) awards ceremony during the World Vaccine Congress in Washington, D.C, to honor the industry’s best and brightest.   Immunovaccine is proud to announce that chief executive officer John Trizzino was awarded this year’s Best Biotech CEO prize during the ceremony.  

In considering candidates for the Best Biotech CEO award, judges evaluated a number of important criteria including:  

• Degree of outstanding commitment to disease prevention and treatment
• Level of exemplary leadership throughout the year
• Contribution to company performance, communication and vision
• Influence within the industry
• Achievements made with regards to company positioning and status

The Maryland Technology Enterprise Institute (Mtech) today announces the winners of the inaugural University of Maryland Business Model Challenge.

The two winning UMD entrepreneur teams were selected from among 44 initial entries and 11 finalist teams, six of whom were selected to present the results they achieved through the Challenge’s multi-week lean startup workshop to an expert panel of judges on April 26 at the University of Maryland.

Earlier this month, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its MoneyTree Report on venture funding for the first quarter of 2013.  The report, which is prepared by NVCA and PriceWaterhouseCoopers LLP using data from Thomson Reuters, indicates that venture capitalists invested $5.9 billion in 863 deals in the first quarter, which constituted a 12% decrease in dollars and a 15% decrease in deals as compared with the fourth quarter of 2012, when $6.7 billion was invested in 1,013 deals (see chart below; data from MoneyTree Reports).